LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors
Sign Up to like & getrecommendations! Published in 2023 at "Translational Lung Cancer Research"
DOI: 10.21037/tlcr-23-39
Abstract: Background Only a fraction of lung adenocarcinoma (LUAD) patients are eligible for immunotherapy. The identification of biomarkers for immunotherapy is crucial to improve patient outcomes. This study aims to systemically analyze LRP1B mutation and its… read more here.
Keywords: lrp1b mutation; lrp1b mutated; luad patients; immune checkpoint ... See more keywords